Crohn’s & Colitis News

Stay up-to-date with the most current news and information about the Crohn's & Colitis Foundation, as well as Crohn's disease and ulcerative colitis.

Below you’ll find our most recent press releases, along with other articles written by the foundation. This media content highlights the public research outcomes related to our initiatives, studies, and clinical trials. In addition, you can read our expert commentary related to research articles culled from external media sources. For a complete list of all our news content, please visit the News Archive section.

If you are a member of the media interested in speaking with a Foundation's spokesperson, contact us today.

Most Recent News

Camp Oasis recieved a $5000 from the Allergan Foundation

Orange County Chapter

Thank you to the Allergan Foundation for investing in Camp Oasis with a $5,000 grant! From Left to right: Bill Meury, Allergan Foundation board member and Executive VP, Chief Commercial Officer; Jonathon Kellerman, Allergan Foundation board member and Executive VP, Global Chief Compliance Officer; Denise Desmond, Crohn’s & Colitis Foundation Orange County Chapter, Executive Director, Gwyn Grenrock, Executive Director of The Allergan Foundation; and Alex Kelly, Allergan Foundation President and Executive VP, Chief Communications Officer.

Crohn’s & Colitis Foundation Receives $5 Million to Fund Innovative Translational and Clinical IBD Research

October 30, 2017

The Crohn’s & Colitis Foundation announced that it received a $5 million pledge from the Litwin family to fund novel, high-risk/high-reward research ideas in the early stage of exploration that could advance the field of inflammatory bowel diseases (IBD) research.

Partnering to Accelerate Science

October 23, 2017

The Crohn’s & Colitis Foundation (the Foundation) celebrates the visionary academic and industry scientists, The Leona M. and Harry B. Helmsley Charitable Trust, IBD patients, and Foundation staff who are partnering to create and sustain IBD Plexus®, a first-of-its-kind research information exchange platform designed to centralize data and biosamples from diverse research studies. The powerful new initiative is designed to advance our understanding of Crohn’s disease and ulcerative colitis, or inflammatory bowel diseases (IBD), and significantly accelerate research driving toward precision medicine and cures for IBD.

Leading Patient Organizations Collaborate to Improve Patient Care in IBD Through Shared Decision-Making

September 11, 2017

The Crohn’s & Colitis Foundation (Foundation) and the American Gastroenterological Association (AGA),in collaboration with Pfizer, Inc., announced today a request for proposal (RFP), around interventions that aim to improve shared decision-making and promote effective health communication between patients with inflammatory bowel disease (IBD) and their clinicians. The goal is to identify and/or establish best practices around shared decision-making that can be easily replicated, broadly disseminated, and widely adopted within the IBD community.

Crohn's & Colitis Foundation Applauds Passage of Restroom Access Legislation in New York State

June 19, 2017

The Crohn’s & Colitis Foundation released the following statement today after the New York State Senate passed the Crohn’s & Colitis Fairness Act (S3295).

Crohn’s & Colitis Foundation Welcomes New National Trustees

April 20, 2017

The Crohn’s & Colitis Foundation (the Foundation) is pleased to announce seven new members of its National Board of Trustees, which oversees the management of the organization’s policies, practices, principles, affairs, funds, and property.

Crohn’s & Colitis Foundation & American Gastroenterological Association Partner to Address Effective Patient-Provider Health Communication in the IBD Community

April 11, 2017

The Crohn’s & Colitis Foundation (the Foundation) and the American Gastroenterological Association (AGA), in collaboration with Pfizer, Inc., announced today a partnership to develop a program to jumpstart advances in the area of shared decision-making in inflammatory bowel diseases (IBD). The program aims to identify gaps in effective communication and the lack of research on how providers and patients can make decisions together and prevent suboptimal treatment.